Protein Information

Name Phogrin
Synonyms IA 2beta; IAR; IAR/receptor like protein tyrosine phosphatase; ICAAR; Islet cell antigen related protein tyrosine phosphatase; Islet cell autoantigen related protein; PTPRN 2…

Compound Information

Name IAA
CAS

Reference List

PubMed Abstract RScore(About this table)
12672406 Koczwara K, Schenker M, Schmid S, Kredel K, Ziegler AG, Bonifacio E: Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Clin Immunol. 2003 Feb;106(2):155-62.


To address this, antibody titer and subclass to insulin, glutamic acid decarboxylase (GAD) 65, IA-2, and IA-2beta proteins were measured by radiobinding assays in untreated or immunized female nonobese diabetic mice.
2(0,0,0,2) Details
10330299 Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, Clare-Salzer M, She JX, Malone J, Crockett S, Schwartz S, Quattrin T, DeSilva M, Vander Vegt P, Notkins A, Krischer J: Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. J Autoimmun. 1999 Jun;12(4):279-87.

2(0,0,0,2) Details
20091020 De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, Van Der Meeren S, Decochez K, Weets I, Keymeulen B, Lampasona V, Wenzlau J, Hutton JC, Pipeleers D, Gorus FK: Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia. 2010 Mar;53(3):517-24. Epub 2009 Nov 29.

2(0,0,0,2) Details
14747289 Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG: Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004 Feb;53(2):384-92.


The highest risks were associated with high-titer IA-2A and IAA, IgG2, IgG3, and/or IgG4 subclass of IA-2A and IAA, and antibodies to the IA-2-related molecule IA-2beta.
1(0,0,0,1) Details
11033022 Woo W, LaGasse JM, Zhou Z, Patel R, Palmer JP, Campus H, Hagopian WA: A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies. J Immunol Methods. 2000 Oct 20;244(1-2):91-103.


The format worked well using diverse antigens such as 35S-met-GAD65, 35S-met-ICA512/IA2, 35S-met-Phogrin, and 125I-insulin, and could be used for simultaneous screening of reactivity to both GAD65 and ICA512/IA2 in the same well.
1(0,0,0,1) Details
18573919 Makinen A, Harkonen T, Ilonen J, Knip M: Characterization of the humoral immune response to islet antigen 2 in children with newly diagnosed type 1 diabetes. Eur J Endocrinol. 2008 Jul;159(1):19-26.


Islet cell antibodies, IAA, GADA, total IA-2A levels, IA-2/IA-2beta epitopes, and isotypes were measured, and human leukocyte antigen (HLA) genotypes were analyzed.
1(0,0,0,1) Details
10479394 Sera Y, Kawasaki E, Abiru N, Ozaki M, Abe T, Takino H, Kondo H, Yamasaki H, Yamaguchi Y, Akazawa S, Nagataki S, Uchigata Y, Matsuura N, Eguchi K: Autoantibodies to multiple islet autoantigens in patients with abrupt onset type 1 diabetes and diabetes diagnosed with urinary glucose screening. J Autoimmun. 1999 Sep;13(2):257-65.


To elucidate the associations of expression of autoantibodies to multiple islet antigens with age of onset and mode of diagnosis of diabetes in Japanese patients with type 1 diabetes, autoantibodies against the protein tyrosine phosphatase-like molecules ICA512 (IA-2) and phogrin (IA-2beta) (ICA512/phogrin-A), GAD (GADA), insulin (IAA), and islet cell cytoplasm (ICA) were determined in sera from 73 Japanese patients with type 1 diabetes obtained within 14 days of diagnosis.
7(0,0,0,7) Details
18193190 Achenbach P, Bonifacio E, Williams AJ, Ziegler AG, Gale EA, Bingley PJ: Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia. 2008 Mar;51(3):488-92. Epub 2008 Jan 9.

2(0,0,0,2) Details